查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080395

藥物研發市場：2026-2032年全球市場預測（依產品、藥物模式、治療領域及最終用戶分類）

Drug Discovery Market by Offering, Drug Modality, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物研發市場將成長至 2,008.4 億美元，複合年成長率為 13.52%。

主要市場統計數據
基準年 2025 826.5億美元
預計年份：2026年 936.3億美元
預測年份：2032年 2008.4億美元
複合年成長率 (%) 13.52%

藥物研發市場簡介

藥物研發正從傳統的、循序漸進的、以化學主導的流程，轉向整合的、數據驅動的運作模式，將生物目標、轉化醫學、臨床證據和生產準備工作在研發早期階段連結起來。儘管如此，這一領域仍然具有很高的科學風險，只有極少數進入人體試驗的候選藥物最終能夠獲得批准，而且整個研發過程通常需要10年，包括藥物發現、臨床前研究、臨床試驗和法規核准等環節。

藥物研發產業的變革

藥物研發格局正因療法種類日益豐富而重塑，這些療法包括精準生物學、多體學、高性能篩檢、表現型分析、基於結構的藥物設計、生物製劑、細胞和基因療法、RNA藥物、抗體藥物偶聯物（ADC）以及靶向蛋白水解藥物。這些變化不僅拓展了藥物研發所針對的疾病範圍，同時也增加了對專業平台、檢驗的資料集和跨學科專業知識的需求。

人工智慧對藥物研發的累積影響

人工智慧如今正對包括標靶辨識、蛋白質結構預測、分子生成、ADMET建模、文獻挖掘、患者分層和臨床實驗室設計在內的許多領域產生累積影響。當人工智慧與高品質實驗數據、可重複的檢測系統、專業知識和前瞻性檢驗相結合時，這種影響尤其顯著。 AlphaFold相關的公共蛋白質結構資料庫現已擴展至包含超過2億個預測結構，這充分展現了計算生物學如何縮短初始假設生成時間並擴大結構資訊的獲取途徑。

全球藥物研發的關鍵區域洞察

亞太地區正逐漸成為大規模藥物研發的重要中心，這得益於中國不斷發展的生物技術生態系統、日本成熟的製藥基礎、韓國在生物製藥和轉化研究方面的優勢、印度的化學和臨床開發能力，以及澳洲從學術界到臨床實踐的創新網路。該地區擁有大規模的患者群體、不斷擴展的臨床試驗能力、強大的合約研究和生產專業知識，以及促進國內生命科學創新（尤其是在腫瘤學、免疫學、感染疾病和先進生物製藥領域）的各項舉措。

我們集團對藥物研發策略的主要觀點

東協正崛起為可操作性臨床研究和生產的中心區域，這得益於新加坡的生物醫學研發中心、馬來西亞和泰國的臨床基礎設施，以及該地區對價格合理的治療方案的廣泛需求。海灣合作理事會（GCC）正投資於基因組學、精準醫療、生物銀行建設和醫療衛生系統現代化，並致力於創造符合國家衛生優先事項、遺傳疾病計畫、腫瘤學、代謝性疾病以及利用數位健康技術產生臨床證據的研究夥伴關係機會。

主要國家藥物研發創新趨勢

美國在全球食品藥物管理局研發領域處於領先地位，這得益於其集中的美國國立衛生研究院（NIH）資助的研究、創業投資、美國食品藥品監督管理局（FDA）監管方面的專業知識、生物技術叢集、專業服務供應商以及大型製藥企業的研發設施。加拿大在人工智慧驅動的藥物研發、結構生物學、腫瘤學、免疫學以及大學衍生公司方面表現出色。同時，墨西哥和巴西在拉丁美洲擁有強大的臨床研究能力、豐富的流行病學數據以及不斷成長的生命科學領域實力，尤其是在臨床試驗方面，這需要廣泛的患者參與以及當地醫療保健系統的積極配合。

藥物研發領導者使用的實用建議

產業領導者在製定產品組合決策時，不僅應考慮藥物發現的數量，還應考慮人類生物學、生物標記的可行性、與競爭對手的差異化以及臨床應用性。為了從人工智慧、自動化和多組體學平台中獲取價值，對資料管治、可互通的實驗室系統、檢測品質、可重複的實驗設計以及 FAIR 資料原則的投資至關重要。

藥物調查方法

本執行摘要採用二手研究方法，基於公開可查且檢驗的資訊來源，包括法規核准數據、同行評審的科學文獻、政府研究機構、臨床實驗室註冊資訊、公共政策文件以及生命科學行業公認的調查方法。尤其著重於可追溯至權威機構（例如FDA、EMA、NIH、WHO、OECD、各國衛生組織以及頂尖科學期刊）的資訊。

結論：主導創新在藥物發現方面具有優越性。

藥物研發正步入一個更一體化的時代，生物學、計算科學、自動化、臨床洞察和監管合規規劃必須作為一個統一的證據系統發揮作用。人工智慧、多體學和先進療法正在提高早期研究的速度和準確性，但永續的價值取決於檢驗的品質、轉化相關性、臨床可行性和嚴格的投資組合管治。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：藥物研發市場：依產品/服務分類

  • 設備/自動化
    • 高效能篩檢系統
      • 微孔盤讀數儀
      • 時間分辨螢光測量裝置
      • 螢光偏振分析裝置
      • AlphaScreen 和 AlphaLISA 檢測系統
      • 自動洗盤機
      • 自動餐盤分配器
      • 自動化培養系統
      • 自動餐盤處理系統
      • 殖民地拾取器
      • 微孔盤封裝開啟系統
    • 自動化液體處理和樣品製備系統
      • 自動液體處理系統
      • 自動移液系統
      • 自動化樣品製備系統
      • 實驗室排班工作流程系統
      • 微孔盤複製器
      • 用於化合物再處理的自動化系統
      • 分配系統
      • 自動稀釋系統
    • 高內涵成像與表現型篩檢系統
      • 共聚焦成像系統
      • 寬場螢光成像系統
      • 活細胞成像系統和無標定成像系統
      • 自動化顯微鏡平台
      • 基於影像的細胞計數系統
      • 類器官和3D培養成像系統
      • 表現型分析系統
    • 實驗室機器人和整合自動化系統
      • 實驗室機械臂
      • 自動化工作單元
    • 分析化學設備
      • 液相層析法系統
      • 氣相層析法系統
      • 液相層析法-質譜聯用系統
      • 串聯式質譜質譜系統
      • 毛細管電泳系統
      • 製備層析法系統
      • 元素分析系統
    • 用於生物物理表徵和耦合分析的儀器
      • 表面電漿共振系統
      • 生物層干涉測量系統
      • 等溫滴定量熱法系統
      • 微尺度熱泳系統
      • 差示掃描螢光測量系統
      • 石英晶體微天平系統
      • 無標定聯合分析系統
    • 結構生物學設備
      • X光晶體結構分析系統
      • 蛋白質結晶篩檢系統
      • 冷凍電鏡系統
      • 冷凍電鏡（Cryo-EM）樣品製備系統
      • 核磁共振波譜系統
      • 小角X光散射裝置
      • 蛋白質晶體成像系統
      • 氫氘交換質譜系統
    • 細胞分析和單細胞分析儀器
      • 流式細胞儀
      • 細胞分選系統
      • 單細胞分析平台
      • 自動細胞計數裝置
      • 細胞活力分析儀
      • 細胞遷移與侵襲分析系統
      • 細胞代謝分析儀
      • 電生理篩檢系統
    • 用於基因組學、轉錄組學、蛋白質組學和多體學的設備
      • 下一代定序系統
      • 單細胞定序平台
      • 太空生物學平台
      • PCR系統
      • 微陣列平台
      • 代謝體學平台
    • 體內藥理學和臨床前研究設備
      • 微型CT系統
      • 體內光學成像系統
      • 微型磁振造影系統
      • 微型正子斷層掃描（MPET）系統
      • 遙測系統
      • 代謝籠系統
      • 疾病監測系統
      • 小動物給藥及取樣系統
  • 試劑、耗材、圖書館
    • 生化試劑
    • 層析法耗材
    • 細胞株和疾病模型
    • 抗體和蛋白質試劑
    • 微孔盤、吸頭和實驗室塑膠製品
    • 檢測試劑盒
    • 化合物庫
  • 軟體
    • 分子建模模擬軟體
    • 實驗室資訊學與工作流程編配
    • 人工智慧和機器學習平台
    • 生物資訊學和多體學分析
    • 數據整合與知識圖譜平台
  • 服務
    • 目標識別與檢驗服務
    • 檢測開發服務
    • 篩檢服務
    • 命中率提升服務
    • 先導藥物最適化服務
    • 製藥和化學服務
    • DMPK 服務
    • 毒理學檢測服務
    • 結構生物學服務

第8章 藥物發現市場：依藥物模式分類

  • 低分子化合物
    • 常規小分子化合物
    • 靶向蛋白分解劑
    • 複雜的低分子化合物
  • 生物製劑
    • 基於抗體的
    • 基於蛋白質
    • 基於胜肽的
  • 核酸療法
    • 基於RNA的
    • 基於DNA的
    • 基因治療載體
  • 細胞療法
    • 免疫細胞療法
    • 再生細胞療法
    • 基因修飾細胞療法

第9章 藥物研發市場：依治療領域分類

  • 心血管系統
  • 代謝性疾病
  • 免疫學
  • 中樞神經系統
  • 腫瘤學
  • 感染疾病
  • 呼吸系統
  • 罕見疾病

第10章 藥物研發市場：依最終用戶分類

  • 製藥公司
  • 生技公司
  • 學術研究機構
  • 受託研究機構

第11章 藥物研發市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 藥物研發市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 藥物研發市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories International, Inc.
  • WuXi AppTec Co., Ltd.
  • Danaher Corporation
  • Eurofins Scientific SE
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Pharmaron Beijing Co., Ltd.
  • Labcorp Holdings Inc.
  • Evotec SE
  • Avantor, Inc.
  • Waters Corporation
  • IQVIA Holdings Inc.
  • Revvity, Inc.
  • Bruker Corporation
  • Illumina, Inc.
  • Syngene International Limited
  • Sartorius AG
  • Bio-Rad Laboratories, Inc.
  • Aragen Life Sciences Limited
  • Corning Incorporated
  • Inotiv, Inc.
  • Curia Global, Inc.
  • Tecan Group Ltd.
  • Schrodinger, Inc.
  • 10x Genomics, Inc.
  • Benchling, Inc.
  • XtalPi Holdings Limited
  • Certara, Inc.
  • Recursion Pharmaceuticals, Inc.
  • AbCellera Biologics Inc.
  • Absci Corporation
  • Adimab, LLC
  • Atomwise Inc.
  • BenevolentAI SA
  • ChemPartner Pharmatech Co., Ltd.
  • Collaborative Drug Discovery, Inc.
  • Crown Bioscience International
  • Dassault Systemes SE
  • Domainex Limited
  • Dotmatics Limited
  • Generate Biomedicines, Inc.
  • Ginkgo Bioworks Holdings, Inc.
  • Iktos SAS
  • Insilico Medicine Cayman TopCo
  • Isomorphic Labs Limited
  • Jubilant Biosys Limited
  • Lonza Group AG
  • OmniAb, Inc.
  • Owkin, Inc.
  • Relay Therapeutics, Inc.
  • Sai Life Sciences Limited
  • Selvita SA
  • Shanghai Medicilon Inc.
  • Sygnature Discovery Limited
  • Taconic Biosciences, Inc.
  • TCG Lifesciences Private Limited
  • The Jackson Laboratory
  • Twist Bioscience Corporation
  • Viva BIoTech Holdings
Product Code: MRR-434CCDA0516F

The Drug Discovery Market is projected to grow by USD 200.84 billion at a CAGR of 13.52% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 82.65 billion
Estimated Year [2026] USD 93.63 billion
Forecast Year [2032] USD 200.84 billion
CAGR (%) 13.52%

Executive Introduction to the Drug Discovery Market

Drug discovery is moving from a sequential, chemistry-led process toward an integrated, data-rich operating model that connects target biology, translational medicine, clinical evidence, and manufacturing readiness earlier in development. The sector remains defined by high scientific risk: only a minority of drug candidates entering human testing ultimately reach approval, and end-to-end development timelines commonly extend across a decade when discovery, preclinical, clinical, and regulatory activities are considered.

Recent approval activity underscores both resilience and selectivity in the innovation system. The U.S. FDA Center for Drug Evaluation and Research approved 55 novel drugs in 2023 and 50 in 2024, demonstrating sustained regulatory throughput after the 2022 slowdown. For executives, the priority is no longer simply generating more molecules; it is improving the probability that the right molecule, therapeutic modality, biomarker strategy, and patient population converge before expensive late-stage trials begin.

Transformative Shifts in the Drug Discovery Landscape

The drug discovery landscape is being reshaped by precision biology, multi-omics, high-throughput screening, phenotypic assays, structure-based drug design, and increasingly diverse therapeutic modalities including biologics, cell and gene therapies, RNA-based medicines, antibody-drug conjugates, and targeted protein degraders. These shifts are expanding the addressable disease space while increasing the need for specialized platforms, validated datasets, and cross-functional expertise.

Capital allocation is also becoming more disciplined. Following tighter financing conditions for biotechnology companies, pipelines are being prioritized around differentiated mechanisms, human genetic validation, biomarker-enriched indications, and assets with clearer clinical and commercial positioning. Strategic partnerships between pharmaceutical companies, biotechnology innovators, contract research organizations, academic centers, and technology providers are therefore becoming central to risk-sharing, translational validation, and speed-to-decision.

Cumulative Impact of Artificial Intelligence on Drug Discovery

Artificial intelligence is now a cumulative force across target identification, protein structure prediction, molecular generation, ADMET modeling, literature mining, patient stratification, and clinical trial design. The impact is strongest when AI is paired with high-quality experimental data, reproducible assay systems, domain expertise, and prospective validation. The public protein-structure database associated with AlphaFold, which expanded to more than 200 million predicted structures, illustrates how computational biology can compress early hypothesis generation and broaden access to structural insight.

However, AI does not remove the biological uncertainty that drives attrition in drug discovery. Model performance depends on data provenance, assay relevance, chemical diversity, bias control, and explainability. The most successful organizations are treating AI as an evidence accelerator rather than a replacement for wet-lab validation, using closed-loop workflows that connect in silico predictions with automated synthesis, biological screening, and iterative experimental learning.

Key Regional Insights Across Global Drug Discovery

Asia-Pacific is becoming a major center for drug discovery scale, supported by China's expanding biotechnology ecosystem, Japan's established pharmaceutical base, South Korea's biologics and translational research strengths, India's chemistry and clinical development capabilities, and Australia's academic-to-clinical innovation networks. The region benefits from large patient populations, growing clinical trial capacity, strong contract research and manufacturing expertise, and policy efforts that encourage domestic life sciences innovation, particularly in oncology, immunology, infectious diseases, and advanced biologics.

North America remains the leading hub for venture-backed biotechnology, academic research commercialization, regulatory precedent, and specialized service providers, with the United States anchoring global innovation density and Canada adding recognized strengths in artificial intelligence, structural biology, and translational research. Europe continues to contribute through strong public research systems, the European Medicines Agency framework, multinational clinical networks, and deep capabilities in biologics, rare diseases, oncology, vaccines, and advanced therapies. Latin America is gaining relevance for clinical trial participation, epidemiological diversity, and regional market access, with Brazil and Mexico playing important roles in patient recruitment and medical research capacity. The Middle East is strengthening precision medicine, genomics, and health innovation strategies through national healthcare transformation programs, while Africa is advancing genomics, infectious disease research, and public health-linked discovery capabilities, although research infrastructure and regulatory capacity remain uneven across countries.

Key Group Insights for Drug Discovery Strategy

ASEAN is emerging as a pragmatic clinical research and manufacturing-adjacent region, supported by Singapore's biomedical R&D base, Malaysia's and Thailand's clinical infrastructure, and broader regional demand for affordable therapeutics. The GCC is investing in genomics, precision medicine, biobanking, and health system modernization, creating opportunities for research partnerships aligned with population health priorities, inherited disease programs, oncology, metabolic disorders, and digital health-enabled clinical evidence generation.

The European Union provides one of the world's most structured regulatory and research environments, strengthened by Horizon Europe funding, cross-border clinical networks, health data initiatives, and harmonized medicines evaluation. BRICS countries offer large patient populations, growing scientific talent, expanding clinical development capacity, and cost-competitive research infrastructure, although regulatory consistency, intellectual property enforcement, and data standards vary by country. The G7 continues to dominate high-value drug discovery, intellectual property generation, advanced therapeutic development, and regulatory science, while NATO-aligned countries contribute substantially to biosecurity, resilient pharmaceutical supply chains, pandemic preparedness, and dual-use biotechnology governance.

Key Country Insights in Drug Discovery Innovation

The United States leads global drug discovery through the concentration of NIH-funded research, venture capital, FDA regulatory experience, biotechnology clusters, specialized service providers, and large pharmaceutical research operations. Canada contributes strengths in AI-enabled drug discovery, structural biology, oncology, immunology, and academic spinouts, while Mexico and Brazil provide important clinical research capacity, epidemiological diversity, and growing life sciences capabilities in Latin America, particularly for trials that require broad patient access and regional healthcare system engagement.

In Europe, the United Kingdom remains a leading center for genomics, clinical research, translational medicine, and biotechnology financing; Germany is strong in medicinal chemistry, biopharma manufacturing, vaccines, and translational medicine; France, Italy, and Spain add major academic hospitals, oncology research, rare disease expertise, and clinical trial networks; and Russia retains scientific depth in chemistry, biology, and infectious disease research but faces constraints from geopolitical and market-access factors. In Asia-Pacific, China has rapidly expanded discovery pipelines and regulatory modernization, India remains a major chemistry, generics, vaccine, and services hub, Japan provides mature pharmaceutical innovation and strong regulatory science, South Korea is recognized for biologics, cell therapy, and digital health integration, and Australia offers efficient early-phase clinical development, strong biomedical research institutions, and globally connected translational research networks.

Actionable Recommendations for Drug Discovery Leaders

Industry leaders should prioritize portfolio decisions around human biology, biomarker feasibility, competitive differentiation, and clinical translatability rather than discovery volume alone. Investments in data governance, interoperable laboratory systems, assay quality, reproducible experimental design, and FAIR data principles are essential for extracting value from AI, automation, and multi-omics platforms.

Vendors should also build partnership models that combine internal scientific judgment with external platform access, including academic collaborations, contract research capabilities, real-world data networks, and computational biology providers. To reduce late-stage failure, teams should integrate CMC, toxicology, regulatory strategy, clinical operations, and payer evidence requirements earlier in discovery and lead optimization, while maintaining clear go/no-go criteria tied to translational evidence.

Research Methodology for Drug Discovery Analysis

This executive summary is developed using a secondary research methodology grounded in publicly available and verifiable sources, including regulatory approval data, peer-reviewed scientific literature, government research agencies, clinical trial registries, public policy documents, and recognized life sciences industry evidence. Emphasis is placed on information traceable to authoritative institutions such as FDA, EMA, NIH, WHO, OECD, national health agencies, and leading scientific publications.

Insights are synthesized through triangulation across regulatory trends, scientific developments, technology adoption, regional policy signals, clinical trial activity, and commercial pipeline behavior. Market interpretation avoids unsupported projections and focuses on observable indicators such as approval counts, R&D activity, clinical infrastructure, therapeutic modality expansion, regulatory modernization, and validated technology adoption patterns.

Conclusion: Drug Discovery Advantage Through Evidence-Led Innovation

Drug discovery is entering a more integrated era in which biology, computation, automation, clinical insight, and regulatory planning must operate as a single evidence system. AI, multi-omics, and advanced therapeutic modalities are improving the speed and precision of early research, but durable value will depend on validation quality, translational relevance, clinical feasibility, and disciplined portfolio governance.

Organizations that combine data integrity, scientific rigor, global partnership networks, and patient-centered development strategies will be best positioned to convert discovery potential into approved therapies. The competitive advantage will belong to teams that can reduce uncertainty earlier, allocate capital more intelligently, and deliver medicines with clearer clinical and therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
      • 4.3.1.1. Scale AI-Enabled Discovery Only Where It Shortens Validated Decision Cycles
      • 4.3.1.2. Capture Modality-Specific Demand From Biologics and Next-Generation Therapeutics
      • 4.3.1.3. Convert Outsourced R&D Demand Into Strategic Discovery Partnerships
      • 4.3.1.4. Prioritize Human-Relevant Models to Reduce Downstream Attrition
    • 4.3.2. Key Restraints
      • 4.3.2.1. Reduce Adoption Friction From High Upfront Cost and ROI Uncertainty
      • 4.3.2.2. Overcome Fragmented Data Infrastructure Before Scaling AI and Automation
    • 4.3.3. Key Opportunities
      • 4.3.3.1. Monetize Integrated Design-Make-Test-Learn Platforms
      • 4.3.3.2. Build Multiomics-to-Insight Offerings for Translational Decision-Making
      • 4.3.3.3. Capture Supplier Diversification Demand With Trusted Regional Capacity
    • 4.3.4. Key Challenges
      • 4.3.4.1. Build Geopolitical Resilience Into Supplier and Data Strategies
      • 4.3.4.2. Prove That Faster Discovery Workflows Improve Translational Success
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Discovery Market, by Offering

  • 7.1. Instruments & Automation
    • 7.1.1. High-Throughput Screening Systems
      • 7.1.1.1. Microplate Readers
      • 7.1.1.2. Time-Resolved Fluorescence Readers
      • 7.1.1.3. Fluorescence Polarization Readers
      • 7.1.1.4. AlphaScreen & AlphaLISA Detection Systems
      • 7.1.1.5. Automated Plate Washers
      • 7.1.1.6. Automated Plate Dispensers
      • 7.1.1.7. Automated Incubation Systems
      • 7.1.1.8. Automated Plate Handling Systems
      • 7.1.1.9. Colony Pickers
      • 7.1.1.10. Microplate Sealing & De-Sealing Systems
    • 7.1.2. Liquid Handling & Sample Preparation Automation Systems
      • 7.1.2.1. Automated Liquid Handling Systems
      • 7.1.2.2. Automated Pipetting Systems
      • 7.1.2.3. Automated Sample Preparation Systems
      • 7.1.2.4. Laboratory Scheduling & Workflow Systems
      • 7.1.2.5. Microplate Replicators
      • 7.1.2.6. Automated Compound Reformatting Systems
      • 7.1.2.7. Dispensing Systems
      • 7.1.2.8. Automated Dilution Systems
    • 7.1.3. High-Content Imaging & Phenotypic Screening Systems
      • 7.1.3.1. Confocal Imaging Systems
      • 7.1.3.2. Widefield Fluorescence Imaging Systems
      • 7.1.3.3. Live-Cell Imaging Systems & Label-Free Imaging Systems
      • 7.1.3.4. Automated Microscopy Platforms
      • 7.1.3.5. Image-Based Cytometry Systems
      • 7.1.3.6. Organoid & Three-Dimensional Culture Imaging Systems
      • 7.1.3.7. Phenotypic Profiling Systems
    • 7.1.4. Laboratory Robotics & Integrated Automation Systems
      • 7.1.4.1. Robotic Laboratory Arms
      • 7.1.4.2. Automated Workcells
    • 7.1.5. Analytical Chemistry Instruments
      • 7.1.5.1. Liquid Chromatography Systems
      • 7.1.5.2. Gas Chromatography Systems
      • 7.1.5.3. Liquid Chromatography-Mass Spectrometry Systems
      • 7.1.5.4. Tandem Mass Spectrometry Systems
      • 7.1.5.5. Capillary Electrophoresis Systems
      • 7.1.5.6. Preparative Chromatography Systems
      • 7.1.5.7. Elemental Analysis Systems
    • 7.1.6. Biophysical Characterization & Binding Analysis Instruments
      • 7.1.6.1. Surface Plasmon Resonance Systems
      • 7.1.6.2. Bio-Layer Interferometry Systems
      • 7.1.6.3. Isothermal Titration Calorimetry Systems
      • 7.1.6.4. Microscale Thermophoresis Systems
      • 7.1.6.5. Differential Scanning Fluorimetry Systems
      • 7.1.6.6. Quartz Crystal Microbalance Systems
      • 7.1.6.7. Label-Free Binding Analysis Systems
    • 7.1.7. Structural Biology Instruments
      • 7.1.7.1. X-Ray Crystallography Systems
      • 7.1.7.2. Protein Crystallization Screening Systems
      • 7.1.7.3. Cryo-Electron Microscopy Systems
      • 7.1.7.4. Cryo-EM Sample Preparation Systems
      • 7.1.7.5. Nuclear Magnetic Resonance Spectroscopy Systems
      • 7.1.7.6. Small-Angle X-Ray Scattering Systems
      • 7.1.7.7. Protein Crystallization Imaging Systems
      • 7.1.7.8. Hydrogen-Deuterium Exchange Mass Spectrometry Systems
    • 7.1.8. Cell Analysis And Single-Cell Analysis Instruments
      • 7.1.8.1. Flow Cytometers
      • 7.1.8.2. Cell Sorting Systems
      • 7.1.8.3. Single-Cell Analysis Platforms
      • 7.1.8.4. Automated Cell Counters
      • 7.1.8.5. Cell Viability Analyzers
      • 7.1.8.6. Cell Migration & Invasion Analysis Systems
      • 7.1.8.7. Cell Metabolism Analyzers
      • 7.1.8.8. Electrophysiology Screening Systems
    • 7.1.9. Genomics, Transcriptomics, Proteomics, & Multiomics Instruments
      • 7.1.9.1. Next-Generation Sequencing Systems
      • 7.1.9.2. Single-Cell Sequencing Platforms
      • 7.1.9.3. Spatial Biology Platforms
      • 7.1.9.4. PCR Systems
      • 7.1.9.5. Microarray Platforms
      • 7.1.9.6. Metabolomics Platforms
    • 7.1.10. In Vivo Pharmacology & Preclinical Research Instruments
      • 7.1.10.1. Micro-Computed Tomography Systems
      • 7.1.10.2. In Vivo Optical Imaging Systems
      • 7.1.10.3. Micro-Magnetic Resonance Imaging Systems
      • 7.1.10.4. Micro-Positron Emission Tomography Systems
      • 7.1.10.5. Telemetry Systems
      • 7.1.10.6. Metabolic Cage Systems
      • 7.1.10.7. Disease Monitoring Systems
      • 7.1.10.8. Small Animal Dosing & Sampling Systems
  • 7.2. Reagents, Consumables, & Libraries
    • 7.2.1. Biochemical Reagents
    • 7.2.2. Chromatography Consumables
    • 7.2.3. Cell Lines & Disease Models;
    • 7.2.4. Antibody & Protein Reagents
    • 7.2.5. Microplates, Tips, & Lab Plastics
    • 7.2.6. Assay Kits
    • 7.2.7. Compound Libraries
  • 7.3. Software
    • 7.3.1. Molecular Modeling & Simulation Software
    • 7.3.2. Lab Informatics & Workflow Orchestration
    • 7.3.3. AI & Machine Learning Platforms
    • 7.3.4. Bioinformatics & Multiomics Analytics
    • 7.3.5. Data Integration & Knowledge Graph Platforms
  • 7.4. Services
    • 7.4.1. Target Identification & Validation Services
    • 7.4.2. Assay Development Services
    • 7.4.3. Screening Services
    • 7.4.4. Hit-To-Lead Services
    • 7.4.5. Lead Optimization Services
    • 7.4.6. Medicinal Chemistry Services
    • 7.4.7. DMPK Services
    • 7.4.8. Toxicology Services
    • 7.4.9. Structural Biology Services

8. Drug Discovery Market, by Drug Modality

  • 8.1. Small Molecules
    • 8.1.1. Conventional Small Molecules
    • 8.1.2. Targeted Protein Degraders
    • 8.1.3. Complex Small Molecules
  • 8.2. Biologics
    • 8.2.1. Antibody-Based
    • 8.2.2. Protein-Based
    • 8.2.3. Peptide-Based
  • 8.3. Nucleic Acid Therapies
    • 8.3.1. RNA-Based
    • 8.3.2. DNA-Based
    • 8.3.3. Gene Therapy Vectors
  • 8.4. Cell Therapies
    • 8.4.1. Immune Cell Therapies
    • 8.4.2. Regenerative Cell Therapies
    • 8.4.3. Engineered Cell Therapies

9. Drug Discovery Market, by Therapeutic Area

  • 9.1. Cardiovascular
  • 9.2. Metabolic
  • 9.3. Immunology
  • 9.4. Central Nervous System
  • 9.5. Oncology
  • 9.6. Infectious Diseases
  • 9.7. Respiratory
  • 9.8. Rare Diseases

10. Drug Discovery Market, by End User

  • 10.1. Pharmaceutical Companies
  • 10.2. Biotechnology Companies
  • 10.3. Academic & Research Institutes
  • 10.4. Contract Research Organizations

11. Drug Discovery Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Drug Discovery Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Drug Discovery Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Thermo Fisher Scientific Inc.
  • 15.2. Charles River Laboratories International, Inc.
  • 15.3. WuXi AppTec Co., Ltd.
  • 15.4. Danaher Corporation
  • 15.5. Eurofins Scientific SE
  • 15.6. Agilent Technologies, Inc.
  • 15.7. Merck KGaA
  • 15.8. Pharmaron Beijing Co., Ltd.
  • 15.9. Labcorp Holdings Inc.
  • 15.10. Evotec SE
  • 15.11. Avantor, Inc.
  • 15.12. Waters Corporation
  • 15.13. IQVIA Holdings Inc.
  • 15.14. Revvity, Inc.
  • 15.15. Bruker Corporation
  • 15.16. Illumina, Inc.
  • 15.17. Syngene International Limited
  • 15.18. Sartorius AG
  • 15.19. Bio-Rad Laboratories, Inc.
  • 15.20. Aragen Life Sciences Limited
  • 15.21. Corning Incorporated
  • 15.22. Inotiv, Inc.
  • 15.23. Curia Global, Inc.
  • 15.24. Tecan Group Ltd.
  • 15.25. Schrodinger, Inc.
  • 15.26. 10x Genomics, Inc.
  • 15.27. Benchling, Inc.
  • 15.28. XtalPi Holdings Limited
  • 15.29. Certara, Inc.
  • 15.30. Recursion Pharmaceuticals, Inc.
  • 15.31. AbCellera Biologics Inc.
  • 15.32. Absci Corporation
  • 15.33. Adimab, LLC
  • 15.34. Atomwise Inc.
  • 15.35. BenevolentAI S.A.
  • 15.36. ChemPartner Pharmatech Co., Ltd.
  • 15.37. Collaborative Drug Discovery, Inc.
  • 15.38. Crown Bioscience International
  • 15.39. Dassault Systemes SE
  • 15.40. Domainex Limited
  • 15.41. Dotmatics Limited
  • 15.42. Generate Biomedicines, Inc.
  • 15.43. Ginkgo Bioworks Holdings, Inc.
  • 15.44. Iktos SAS
  • 15.45. Insilico Medicine Cayman TopCo
  • 15.46. Isomorphic Labs Limited
  • 15.47. Jubilant Biosys Limited
  • 15.48. Lonza Group AG
  • 15.49. OmniAb, Inc.
  • 15.50. Owkin, Inc.
  • 15.51. Relay Therapeutics, Inc.
  • 15.52. Sai Life Sciences Limited
  • 15.53. Selvita S.A.
  • 15.54. Shanghai Medicilon Inc.
  • 15.55. Sygnature Discovery Limited
  • 15.56. Taconic Biosciences, Inc.
  • 15.57. TCG Lifesciences Private Limited
  • 15.58. The Jackson Laboratory
  • 15.59. Twist Bioscience Corporation
  • 15.60. Viva Biotech Holdings

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG DISCOVERY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG DISCOVERY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG DISCOVERY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG MODALITY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS & AUTOMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS & AUTOMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS & AUTOMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIGH-THROUGHPUT SCREENING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIGH-THROUGHPUT SCREENING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIGH-THROUGHPUT SCREENING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICROPLATE READERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICROPLATE READERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROPLATE READERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TIME-RESOLVED FLUORESCENCE READERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TIME-RESOLVED FLUORESCENCE READERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TIME-RESOLVED FLUORESCENCE READERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FLUORESCENCE POLARIZATION READERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FLUORESCENCE POLARIZATION READERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FLUORESCENCE POLARIZATION READERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALPHASCREEN & ALPHALISA DETECTION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALPHASCREEN & ALPHALISA DETECTION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALPHASCREEN & ALPHALISA DETECTION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED PLATE WASHERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATED PLATE WASHERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATED PLATE WASHERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATED PLATE DISPENSERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATED PLATE DISPENSERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATED PLATE DISPENSERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATED INCUBATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATED INCUBATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATED INCUBATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATED PLATE HANDLING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATED PLATE HANDLING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATED PLATE HANDLING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLONY PICKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLONY PICKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLONY PICKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICROPLATE SEALING & DE-SEALING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROPLATE SEALING & DE-SEALING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICROPLATE SEALING & DE-SEALING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID HANDLING & SAMPLE PREPARATION AUTOMATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID HANDLING & SAMPLE PREPARATION AUTOMATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIQUID HANDLING & SAMPLE PREPARATION AUTOMATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED LIQUID HANDLING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED LIQUID HANDLING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATED LIQUID HANDLING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATED PIPETTING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATED PIPETTING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATED PIPETTING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATED SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATED SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATED SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LABORATORY SCHEDULING & WORKFLOW SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LABORATORY SCHEDULING & WORKFLOW SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LABORATORY SCHEDULING & WORKFLOW SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MICROPLATE REPLICATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MICROPLATE REPLICATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MICROPLATE REPLICATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATED COMPOUND REFORMATTING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATED COMPOUND REFORMATTING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATED COMPOUND REFORMATTING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DISPENSING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DISPENSING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DISPENSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATED DILUTION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATED DILUTION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATED DILUTION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HIGH-CONTENT IMAGING & PHENOTYPIC SCREENING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIGH-CONTENT IMAGING & PHENOTYPIC SCREENING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HIGH-CONTENT IMAGING & PHENOTYPIC SCREENING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONFOCAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONFOCAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONFOCAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WIDEFIELD FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WIDEFIELD FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WIDEFIELD FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVE-CELL IMAGING SYSTEMS & LABEL-FREE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIVE-CELL IMAGING SYSTEMS & LABEL-FREE IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVE-CELL IMAGING SYSTEMS & LABEL-FREE IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATED MICROSCOPY PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATED MICROSCOPY PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATED MICROSCOPY PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMAGE-BASED CYTOMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMAGE-BASED CYTOMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMAGE-BASED CYTOMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORGANOID & THREE-DIMENSIONAL CULTURE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGANOID & THREE-DIMENSIONAL CULTURE IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORGANOID & THREE-DIMENSIONAL CULTURE IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHENOTYPIC PROFILING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHENOTYPIC PROFILING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHENOTYPIC PROFILING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LABORATORY ROBOTICS & INTEGRATED AUTOMATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LABORATORY ROBOTICS & INTEGRATED AUTOMATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LABORATORY ROBOTICS & INTEGRATED AUTOMATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ROBOTIC LABORATORY ARMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ROBOTIC LABORATORY ARMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ROBOTIC LABORATORY ARMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOMATED WORKCELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOMATED WORKCELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOMATED WORKCELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANALYTICAL CHEMISTRY INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANALYTICAL CHEMISTRY INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANALYTICAL CHEMISTRY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL LIQUID CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIQUID CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL LIQUID CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GAS CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GAS CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GAS CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TANDEM MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TANDEM MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TANDEM MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CAPILLARY ELECTROPHORESIS SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CAPILLARY ELECTROPHORESIS SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CAPILLARY ELECTROPHORESIS SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREPARATIVE CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PREPARATIVE CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PREPARATIVE CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ELEMENTAL ANALYSIS SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ELEMENTAL ANALYSIS SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ELEMENTAL ANALYSIS SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHYSICAL CHARACTERIZATION & BINDING ANALYSIS INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHYSICAL CHARACTERIZATION & BINDING ANALYSIS INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHYSICAL CHARACTERIZATION & BINDING ANALYSIS INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SURFACE PLASMON RESONANCE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SURFACE PLASMON RESONANCE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SURFACE PLASMON RESONANCE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIO-LAYER INTERFEROMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIO-LAYER INTERFEROMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIO-LAYER INTERFEROMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ISOTHERMAL TITRATION CALORIMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ISOTHERMAL TITRATION CALORIMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ISOTHERMAL TITRATION CALORIMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MICROSCALE THERMOPHORESIS SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MICROSCALE THERMOPHORESIS SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MICROSCALE THERMOPHORESIS SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DIFFERENTIAL SCANNING FLUORIMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIFFERENTIAL SCANNING FLUORIMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DIFFERENTIAL SCANNING FLUORIMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL QUARTZ CRYSTAL MICROBALANCE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL QUARTZ CRYSTAL MICROBALANCE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL QUARTZ CRYSTAL MICROBALANCE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL LABEL-FREE BINDING ANALYSIS SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL LABEL-FREE BINDING ANALYSIS SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL LABEL-FREE BINDING ANALYSIS SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL STRUCTURAL BIOLOGY INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL STRUCTURAL BIOLOGY INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL STRUCTURAL BIOLOGY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL X-RAY CRYSTALLOGRAPHY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL X-RAY CRYSTALLOGRAPHY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL X-RAY CRYSTALLOGRAPHY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PROTEIN CRYSTALLIZATION SCREENING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL PROTEIN CRYSTALLIZATION SCREENING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PROTEIN CRYSTALLIZATION SCREENING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CRYO-ELECTRON MICROSCOPY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRYO-ELECTRON MICROSCOPY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CRYO-ELECTRON MICROSCOPY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRYO-EM SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CRYO-EM SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CRYO-EM SAMPLE PREPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL SMALL-ANGLE X-RAY SCATTERING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL SMALL-ANGLE X-RAY SCATTERING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL SMALL-ANGLE X-RAY SCATTERING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PROTEIN CRYSTALLIZATION IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROTEIN CRYSTALLIZATION IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PROTEIN CRYSTALLIZATION IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CELL ANALYSIS AND SINGLE-CELL ANALYSIS INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL ANALYSIS AND SINGLE-CELL ANALYSIS INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CELL ANALYSIS AND SINGLE-CELL ANALYSIS INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL FLOW CYTOMETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL FLOW CYTOMETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL FLOW CYTOMETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CELL SORTING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL SORTING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CELL SORTING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL SINGLE-CELL ANALYSIS PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL SINGLE-CELL ANALYSIS PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL SINGLE-CELL ANALYSIS PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL AUTOMATED CELL COUNTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL AUTOMATED CELL COUNTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL AUTOMATED CELL COUNTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL VIABILITY ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CELL VIABILITY ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL VIABILITY ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CELL MIGRATION & INVASION ANALYSIS SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL MIGRATION & INVASION ANALYSIS SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CELL MIGRATION & INVASION ANALYSIS SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL METABOLISM ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CELL METABOLISM ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL METABOLISM ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ELECTROPHYSIOLOGY SCREENING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL ELECTROPHYSIOLOGY SCREENING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ELECTROPHYSIOLOGY SCREENING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENOMICS, TRANSCRIPTOMICS, PROTEOMICS, & MULTIOMICS INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GENOMICS, TRANSCRIPTOMICS, PROTEOMICS, & MULTIOMICS INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENOMICS, TRANSCRIPTOMICS, PROTEOMICS, & MULTIOMICS INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION SEQUENCING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION SEQUENCING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION SEQUENCING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL SINGLE-CELL SEQUENCING PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL SINGLE-CELL SEQUENCING PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL SINGLE-CELL SEQUENCING PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL SPATIAL BIOLOGY PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL SPATIAL BIOLOGY PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL SPATIAL BIOLOGY PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL PCR SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL PCR SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL PCR SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL MICROARRAY PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL MICROARRAY PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL MICROARRAY PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL METABOLOMICS PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL METABOLOMICS PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL METABOLOMICS PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL IN VIVO PHARMACOLOGY & PRECLINICAL RESEARCH INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL IN VIVO PHARMACOLOGY & PRECLINICAL RESEARCH INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL IN VIVO PHARMACOLOGY & PRECLINICAL RESEARCH INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL MICRO-COMPUTED TOMOGRAPHY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL MICRO-COMPUTED TOMOGRAPHY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL MICRO-COMPUTED TOMOGRAPHY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL IN VIVO OPTICAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL IN VIVO OPTICAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL IN VIVO OPTICAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL MICRO-MAGNETIC RESONANCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL MICRO-MAGNETIC RESONANCE IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL MICRO-MAGNETIC RESONANCE IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL MICRO-POSITRON EMISSION TOMOGRAPHY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL MICRO-POSITRON EMISSION TOMOGRAPHY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL MICRO-POSITRON EMISSION TOMOGRAPHY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL TELEMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL TELEMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL TELEMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL METABOLIC CAGE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL METABOLIC CAGE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL METABOLIC CAGE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL DISEASE MONITORING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL DISEASE MONITORING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL DISEASE MONITORING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL SMALL ANIMAL DOSING & SAMPLING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL SMALL ANIMAL DOSING & SAMPLING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL SMALL ANIMAL DOSING & SAMPLING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL REAGENTS, CONSUMABLES, & LIBRARIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL REAGENTS, CONSUMABLES, & LIBRARIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL REAGENTS, CONSUMABLES, & LIBRARIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL BIOCHEMICAL REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL BIOCHEMICAL REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL BIOCHEMICAL REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL CHROMATOGRAPHY CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL CHROMATOGRAPHY CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL CHROMATOGRAPHY CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL CELL LINES & DISEASE MODELS; MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL CELL LINES & DISEASE MODELS; MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL CELL LINES & DISEASE MODELS; MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL ANTIBODY & PROTEIN REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL ANTIBODY & PROTEIN REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL ANTIBODY & PROTEIN REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL MICROPLATES, TIPS, & LAB PLASTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL MICROPLATES, TIPS, & LAB PLASTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL MICROPLATES, TIPS, & LAB PLASTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL ASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL ASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL ASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL COMPOUND LIBRARIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL COMPOUND LIBRARIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL COMPOUND LIBRARIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL MOLECULAR MODELING & SIMULATION SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL MOLECULAR MODELING & SIMULATION SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL MOLECULAR MODELING & SIMULATION SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL LAB INFORMATICS & WORKFLOW ORCHESTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL LAB INFORMATICS & WORKFLOW ORCHESTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL LAB INFORMATICS & WORKFLOW ORCHESTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL AI & MACHINE LEARNING PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL AI & MACHINE LEARNING PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL AI & MACHINE LEARNING PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL BIOINFORMATICS & MULTIOMICS ANALYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL BIOINFORMATICS & MULTIOMICS ANALYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL BIOINFORMATICS & MULTIOMICS ANALYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL DATA INTEGRATION & KNOWLEDGE GRAPH PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL DATA INTEGRATION & KNOWLEDGE GRAPH PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL DATA INTEGRATION & KNOWLEDGE GRAPH PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 292. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL TARGET IDENTIFICATION & VALIDATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 295. GLOBAL TARGET IDENTIFICATION & VALIDATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL TARGET IDENTIFICATION & VALIDATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL ASSAY DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 298. GLOBAL ASSAY DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. GLOBAL ASSAY DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL SCREENING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 301. GLOBAL SCREENING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 302. GLOBAL SCREENING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL HIT-TO-LEAD SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 304. GLOBAL HIT-TO-LEAD SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 305. GLOBAL HIT-TO-LEAD SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 306. GLOBAL LEAD OPTIMIZATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 307. GLOBAL LEAD OPTIMIZATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. GLOBAL LEAD OPTIMIZATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. GLOBAL MEDICINAL CHEMISTRY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 310. GLOBAL MEDICINAL CHEMISTRY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 311. GLOBAL MEDICINAL CHEMISTRY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL DMPK SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 313. GLOBAL DMPK SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. GLOBAL DMPK SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL TOXICOLOGY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 316. GLOBAL TOXICOLOGY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. GLOBAL TOXICOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 318. GLOBAL STRUCTURAL BIOLOGY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 319. GLOBAL STRUCTURAL BIOLOGY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. GLOBAL STRUCTURAL BIOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 321. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG MODALITY, 2018-2032 (USD MILLION)
  • TABLE 322. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 323. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 324. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. GLOBAL CONVENTIONAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 326. GLOBAL CONVENTIONAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. GLOBAL CONVENTIONAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 328. GLOBAL TARGETED PROTEIN DEGRADERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 329. GLOBAL TARGETED PROTEIN DEGRADERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 330. GLOBAL TARGETED PROTEIN DEGRADERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 331. GLOBAL COMPLEX SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 332. GLOBAL COMPLEX SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 333. GLOBAL COMPLEX SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 334. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 335. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 336. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2